NCBiotech News

We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.

PRA logo , ICON logo
North Carolina's Research Triangle, birthplace and global centerpiece of the huge contract research enterprise, is losing a homegrown headquarters with a $12 billion buyout of PRA Health Sciences by Ireland-based ICON plc.
Propella logo
Pittsboro-based startup Propella Therapeutics is teaming up with the National Cancer Institute (NCI) to evaluate its new treatment for metastatic prostate cancer.
Sam Taylor
Sam Taylor, a founder and long-time president of the state's life sciences trade association, NCBIO, has died of pancreatic cancer.
Disseminated Intravascular Coagulation Blood Disorder

[Editor's note from Tracey du Laney, Ph.D., the North Carolina Biotechnology Center’s senior director of Science and Technology Development, who oversees this grant: This line of research exemplifies what a Flash Grant is all about. The nanosphere  technology that Dr. Brown’s team is developing addresses a large patient population with unmet needs in a new way. It could lead to new therapeutics to treat disseminated intravascular coagulation (DIC). DIC results not just from sepsis and cancer, but also has emerged as a life-threatening condition with COVID-19.

Model of ACT implant with anatomy
Advanced Chemotherapy Technologies, a Raleigh medical device startup developing a way to improve the treatment of pancreatic cancer, has added $2.5 million in funding to support clinical testing of its technology.
Humacyte exterior
Durham-based regenerative medicine company Humacyte is going public in a novel deal that will give it a market capitalization of $1.1 billion.
Rescindo logo
A drug being developed by Cary-based Rescindo Therapeutics for treating a rare developmental disorder in children has received two special designations from the FDA.
G1 logoG1 Therapeutics of Research Triangle Park transformed into a commercial-stage company overnight upon the approval of its first drug by the U.S. Food and Drug Administration.
RTP's G1 Therapeutics has received FDA approval of its first drug, for protecting bone marrow from chemotherapy damage.
BTEC scene
Life sciences manufacturing companies in North Carolina expanded their collective workforce by more than 2020, in sharp contrast to the global economic downturn wrought by the COVID-19 pandemic.
Machelle Sanders
Veteran pharmaceutical company executive Machelle Sanders, a North Carolina native and former board member of the North Carolina Biotechnology Center, was named Secretary of the Department of Commerce today by Governor Roy Cooper.
NC IDEA is welcoming entrepreneurs statewide to submit MICRO and SEED Grant applications until March 1.
Knee photo
Medical device maker Bioventus is the latest North Carolina life sciences firm joining the public markets, raising $104 million from its initial public offering.
NC A&T logo
NC A&T logo

A $1.5 million gift from the North Carolina GlaxoSmithKline Foundation will help community college students pursue science, technology, engineering and math (STEM) degrees at North Carolina Agricultural and Technical State University in Greensboro.

Woman using Spencer Health Solutions device
Durham's Spencer Health Solutions is striking up alliances with pharma companies, using its smart medication dispensing technology to monitor how patients take their drugs at home while also providing the drug makers insight about how the medicines in clinical testing are working.
Heat Bio logo
Durham-based Heat Biologics reported positive interim results from a phase 2 clinical trial of its therapy to treat advanced non-small cell lung cancer.